SG11201803867TA - Sodium channel blocker - Google Patents

Sodium channel blocker

Info

Publication number
SG11201803867TA
SG11201803867TA SG11201803867TA SG11201803867TA SG11201803867TA SG 11201803867T A SG11201803867T A SG 11201803867TA SG 11201803867T A SG11201803867T A SG 11201803867TA SG 11201803867T A SG11201803867T A SG 11201803867TA SG 11201803867T A SG11201803867T A SG 11201803867TA
Authority
SG
Singapore
Prior art keywords
sodium channel
channel blocker
present
abtract
prevention
Prior art date
Application number
SG11201803867TA
Other languages
English (en)
Inventor
Hyung-Geun Lee
Il-Hwan Kim
Myunggi Jung
Hyo Shin Kim
Chun Ho Lee
Sun Ah Jun
Ji Sung Yoon
Sung-Young Kim
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of SG11201803867TA publication Critical patent/SG11201803867TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/50Nitrogen atoms bound to hetero atoms
    • C07D277/52Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
SG11201803867TA 2015-11-13 2016-11-11 Sodium channel blocker SG11201803867TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150159637 2015-11-13
PCT/KR2016/013029 WO2017082688A1 (fr) 2015-11-13 2016-11-11 Bloqueur des canaux sodiques

Publications (1)

Publication Number Publication Date
SG11201803867TA true SG11201803867TA (en) 2018-06-28

Family

ID=58695815

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803867TA SG11201803867TA (en) 2015-11-13 2016-11-11 Sodium channel blocker

Country Status (30)

Country Link
US (1) US10227338B2 (fr)
EP (1) EP3375782B1 (fr)
JP (1) JP6559894B2 (fr)
KR (1) KR102245930B1 (fr)
CN (1) CN108349963B (fr)
AU (1) AU2016351526B2 (fr)
BR (1) BR112018009754B1 (fr)
CA (1) CA3003119C (fr)
CL (1) CL2018001281A1 (fr)
CO (1) CO2018005064A2 (fr)
EC (1) ECSP18038014A (fr)
ES (1) ES2821962T3 (fr)
HK (1) HK1251229A1 (fr)
HR (1) HRP20201695T1 (fr)
HU (1) HUE052569T2 (fr)
MA (1) MA43231B1 (fr)
MX (1) MX2018005940A (fr)
MY (1) MY194015A (fr)
NZ (1) NZ742069A (fr)
PE (1) PE20181301A1 (fr)
PH (1) PH12018500999A1 (fr)
PL (1) PL3375782T3 (fr)
PT (1) PT3375782T (fr)
RS (1) RS60927B1 (fr)
RU (1) RU2705578C1 (fr)
SA (1) SA518391540B1 (fr)
SG (1) SG11201803867TA (fr)
SI (1) SI3375782T1 (fr)
TN (1) TN2018000157A1 (fr)
WO (1) WO2017082688A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019114964A (ru) * 2016-10-17 2020-11-17 Дженентек, Инк. Терапевтические средства и способы их применения
WO2020052509A1 (fr) * 2018-09-10 2020-03-19 成都康弘药业集团股份有限公司 Composé sulfonamide servant de bloqueur de canaux sodiques et ses utilisations
CN112759559B (zh) * 2019-11-06 2022-08-12 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
PT1612208E (pt) * 2001-03-12 2011-10-12 Ono Pharmaceutical Co Composto de n-fenilarilsulfonamida, composição farmacêutica compreendendo o composto como ingrediente activo, intermediários de síntese para o composto e processos para a sua preparação
JP2006290791A (ja) * 2005-04-11 2006-10-26 Astellas Pharma Inc アゾール置換スルホニルベンゼン誘導体
US20090221581A1 (en) * 2005-05-25 2009-09-03 Philipp Wabnitz Methods of treating pain
US7888345B2 (en) 2006-06-09 2011-02-15 Merck Sharp & Dohme Corp. Benzaepinones as sodium channel blockers
CA2695613A1 (fr) * 2006-12-19 2008-06-26 Pharmos Corporation Derives sulfonamides avec indications therapeutiques
SA08290245B1 (ar) 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
JP2008290791A (ja) * 2007-05-22 2008-12-04 Funai Electric Co Ltd 画像形成装置
US8124610B2 (en) * 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
PT2385938E (pt) * 2009-01-12 2015-06-02 Pfizer Ltd Derivados de sulfonamida
EP2593432B1 (fr) 2010-07-12 2014-10-22 Pfizer Limited Dérivés de n-sulfonylbenzamide utiles comme inhibiteurs du canal sodique voltage-dépendant
US9481677B2 (en) 2011-10-31 2016-11-01 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
EP2788332A1 (fr) 2011-12-07 2014-10-15 Amgen, Inc. Inhibiteurs aryle et hétéroaryle bicycliques des canaux calciques
CA2857603C (fr) 2011-12-15 2016-08-02 Pfizer Limited Derives de sulfonamide
WO2013093688A1 (fr) 2011-12-19 2013-06-27 Pfizer Limited Dérivés sulfonamides et leur utilisation en tant qu'inhibiteurs de vgsc
WO2013177224A1 (fr) 2012-05-22 2013-11-28 Genentech, Inc. Benzamides n-substitués et leur utilisation dans le traitement de la douleur
US9376429B2 (en) * 2012-10-15 2016-06-28 Daewoong Pharmaceutical Co., Ltd. Sodium channel blockers, preparation method thereof and use thereof
US20170145003A1 (en) * 2014-02-27 2017-05-25 Mark G. DeGiacomo Heterocyclic inhibitors of the sodium channel

Also Published As

Publication number Publication date
EP3375782A4 (fr) 2019-05-15
MY194015A (en) 2022-11-08
HRP20201695T1 (hr) 2020-12-25
HUE052569T2 (hu) 2021-05-28
BR112018009754A8 (pt) 2019-02-26
RS60927B1 (sr) 2020-11-30
RU2705578C1 (ru) 2019-11-08
JP2018533606A (ja) 2018-11-15
MA43231B1 (fr) 2020-08-31
WO2017082688A1 (fr) 2017-05-18
ES2821962T3 (es) 2021-04-28
TN2018000157A1 (en) 2019-10-04
CO2018005064A2 (es) 2018-06-20
MX2018005940A (es) 2018-08-14
KR20170056461A (ko) 2017-05-23
PT3375782T (pt) 2020-08-05
EP3375782B1 (fr) 2020-07-29
CA3003119A1 (fr) 2017-05-18
CA3003119C (fr) 2019-10-22
SA518391540B1 (ar) 2021-04-06
SI3375782T1 (sl) 2020-10-30
CL2018001281A1 (es) 2018-08-31
BR112018009754A2 (pt) 2018-11-06
AU2016351526A1 (en) 2018-05-17
PH12018500999A1 (en) 2019-01-28
CN108349963A (zh) 2018-07-31
ECSP18038014A (es) 2018-05-31
PE20181301A1 (es) 2018-08-09
AU2016351526B2 (en) 2019-02-21
PL3375782T3 (pl) 2021-02-22
US10227338B2 (en) 2019-03-12
US20180346459A1 (en) 2018-12-06
HK1251229A1 (zh) 2019-01-25
CN108349963B (zh) 2021-03-30
JP6559894B2 (ja) 2019-08-14
BR112018009754B1 (pt) 2024-01-23
NZ742069A (en) 2019-08-30
KR102245930B1 (ko) 2021-04-29
EP3375782A1 (fr) 2018-09-19

Similar Documents

Publication Publication Date Title
PH12019500480A1 (en) Pyridine compound
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
MY197698A (en) Oxysterols and methods of use thereof
TN2020000081A1 (en) Amino-methyl piperidine derivative as kinase inhibitor
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
MX362383B (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
EA201991253A1 (ru) Бензодиазолиевые соединения в качестве ингибиторов enac
MX2019002369A (es) Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial.
MY193239A (en) Novel b-lactamase inhibitors
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
PH12018500999A1 (en) Sodium channel blocker
SA520411726B1 (ar) مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
NZ748746A (en) Pyrazolopyrimidine derivatives as kinase inhibitor